HEALTHCARE
Eli Lilly completes acquisition of EtaiBexli, adding treatment-resistant depression programs
On 2026-09-20 WISH-TV reported that Indianapolis-based Eli Lilly announced the completion of its acquisition of biopharmaceutical company EtaiBexli, which is developing treatments for mental health conditions including treatment-resistant depression.
BUSINESSINDY BRIEFBy BusinessIndy Editorial StaffPublished September 20, 2026 at 8:31 PM EDT
On 2026-09-20, WISH-TV reported that Indianapolis-based Eli Lilly announced completion of its acquisition of biopharmaceutical company EtaiBexli. EtaiBexli is described as developing treatments for mental health conditions, including treatment-resistant depression.
BusinessIndy examines this development and its implications for Indiana businesses and communities using the linked sources.